KIDNEY TRANSPLANTATION FOR THE INTERNIST

Marc Richards MD South Florida Kidney Disease and Hypertension Specialists BRRH Grand Rounds 5.8.2018

Goal of Lecture:





OUTLINE

- □ CKD -> ESRD
- Workup for Transplant
- UNOS Registry
- Immune Suppression
- Infectious Complications
- Noninfectious Complications
- Prognosis

CKD STAGES

				Persistent Albuminuria Categories, Description and Range		
			Normal to mildly increased	Moderately increased	Severely increased	
				<30 mg/g (<3 mg/mmol)	30-300 mg/g (3-30 mg/mmol)	>300 mg/g (>30 mg/mmol)
GFR Categories (mL/min/1.73 m ²) Stage, Description, and Range	1	Normal or high	≥90	1 if CKD	1	2
	2	Mildly decreased	60–89	1 if CKD	1	2
	3a	Mildly to moderately decreased	45–59	1	2	3
	3b	Moderately to severely decreased	30–44	2	3	3
	4	Severely decreased	15–29	3	3	4+
	5	Kidney failure	<15	4+	4+	4+

Annals of Int Med.

CKD/ESRD Prevalence


pop in millions Stage 3 CKD, by Age Group 30 18 Ages 20-39 Ages 60+ 26.0% 16 25 24.2% 24.5% 14 20 12 18.8% 10 Percent 8 10 6 4 5 700,000 336,000 2 0.3% 0.2% 0.1% 0.1% 0 0 NHANES NHANES NHANES NHANES 1988-1994 1999-2002 2003-2006 2001-2008 Stage 1 stage 2 stage 3 stage 4 stage 5 Years

Coresh et al. JAMA 2007; NIDDK


Percent of Population with


Prevalence of ESRD is Rising

Incidence leveling off but prevalence up




HD vs TRANSPLANT






Wait List

□ More eligible patients and plateauing living donor rates → higher WL times








How to increase # kidney txp?

- "Opt-out" vs "opt-in" policy
- Dispelling myths re: living donation
- Swaps/Chains
- Expanded Criteria Donor (ECD) List
 - □ > 60
 - >50 plus 2 of 3: HTN, CVA, Cr > 1.5
- Accepting kidneys from previously "marginal" living donors
- ABOi transplants
- □ HCV+ Donor


Transplant Benefits: \$\$\$

ESRD costs Medicare \$29 billion per year!!!




NIDDK

Transplant Benefits: Mortality




Transplant Benefits: Mortality


Mortality (% Per Year) Dialysis vs. Transplant




Less mortality and less rejection

10-year General Graft Survival Rates






More living transplant patients



NIDDK

Kidney Transplant Referral

Eligible if irreversible progression to GFR < 20mL/min</p>



Who can be referred?

Just about anybody!

Absolute contraindications:


Active malignancy

- Active untreated infection
- Severe irreversible extrarenal disease
- Psychosocial issues
- Note what's <u>not</u> on this list:

Age, HIV, HCV, patients eligible for dual organ transplant

Florida Organ Procurement Offices (OPO)

- Our local zone:
 - UM/Jackson
 - Cleveland Clinic- FL
 - Memorial Hollywood *new*
- Pts can be referred to multiple zones



Recipient Pre-txp Workup

- Basic Labs
- Drug screen
- Infection screen
- Age appropriate cancer screening
- HLA/ABO testing
- Cardiac testing based on RF
- Dental clearance
- □ Etc

Living Donation

Medical, Surgical, and Psychosocial evaluation
 Purpose: protect the donor!


Periop 90 day mortality- 1 in 3000 (0.03%)

□ Long term:

- No change in mortality compared to controls
- Slightly increased relative risk of HTN, PEC, ESRD
 - (absolute risk low)

Kidney Transplant Surgery

- 🗆 lliac Fossa
- Anastomoses:
 Renal A/V
 - Ureter
- Native kidneys remain!



Transplant Medications




Figure 2. Individual Immunosuppressive Drugs and Sites of Action in the Three-Signal Model.

Halloran et al NEJM 2004 351;26

Maintenance therapy

- Calcineurin Inhibitors
 - Tacrolimus > Cyclosporine
 - Inhibits transcription of IL2 and other cytokines \rightarrow less T cell activation
- Antiproliferatives
 - Mycophenolate > Azathioprine
 - Interferes with DNA/purine synthesis
- Steroids
 - Prevents cytokine production by T cells and APCs
- Also: mTOR inhibitors, Belatacept


Drug Toxicity

Combination	Hypertension	Diabetes	Hyperlipidemia
Azathioprine	0	0	0
Prednisone	++	++	++
Cyclosporine	+++	+	+++
Tacrolimus 🗙	++	++++	++
MMF	0	0	0
Sirolimus	0	++	++++
Everolimus	0	++	
Belatacept	0	0	0


CNI Nephrotoxicity

Glomerular afferent/efferent arteriolar vasoconstriction

Light micrograph showing cyclosporine-induced arteriolopathy



Light micrograph of cyclosporine-induced renal arteriolopathy. There is replacement of smooth muscle cells in the media by proteinaceous material (arrowheads), eventually leading to virtual obliteration of the vascular lumen (arrow). Light micrograph showing cyclosporine-induced renal tubular injury



Light micrograph shows vacuolization of the proximal tubular cells (arrows) due to cyclosporine nephrotoxicity.

CNI Toxicity (cotd)

- Hyperkalemia (hypoaldo)
- Hypomagnesemia (p glycoprotein down with diarrhea)
- Gout
- □ DM (T>C)
- HTN
- HLD
- CsA- hirsutism + gum hyperplasia
- Tacro- alopecia, neuro

CNI Drug Interactions

Cleared by Cytochrome P450

Increase CNI Ievels	 Amiodarone ART boosting agents (eg, ritonavir, cobicistat) Azole antifungals (eg, fluconazole, posaconazole, voriconazole) Grapefruit juice HIV protease inhibitors (eg, atazanavir, nelfinavir, saquinavir) Macrolide antibiotics (except azithromycin) Non-dihydropyridine calcium channel blockers
Decrease CNI levels	 Antiseizure drugs, enzyme-inducing (eg, carbamazepine, fosphenytoin, oxcarbazepine, phenobarbital, phenytoin, primidone) Enzalutamide Nafcillin Rifamycins (eg, rifabutin, rifampin, rifapentine) St. John's wort

Antiproliferatives


MMF or AZA

- Careful:
 - Leukopenia
 - GI symptoms (MMF)
 - Drug Interaction of Note: AZA + Allopurinol -> severe marrow suppression

Belatacept

Inhibits T cell activation through costimulation blockade


No known nephrotoxicity or adverse CV effects




Pop Quiz

What is the most common cause of kidney transplant failure?

Mortality has not
 Improved much in active
 Transplant pts




Causes of death in kidney transplant patients



HTN

- Target BP 130/80 (no real data)
- CaChB- may reduce CNI induced vasoconstriction
 Non-DHP will raise CNI levels
- BB may reduce CV mortality
- - Retrospective study \rightarrow
 - Risks:
 - High K
 - Anemia
 - Transplant RAS/Rejection
 - Confounding rise in Cr



HLD- STATINS

ALERT Trial- AJT 2005

Fluvastatin 80 v placebo


(a)

LDL levels lowered

RCT

- Fluvastatin
- Atorvastatin
- Pravastatin

 (others can interact with CNIs)



Time (years)


Statin adjuncts

□ Not well studied and all have risks/SEs

- Zetia
 - Can interact with CNI (Vytorin)
 - GI SEs
- Fibrates
 - Rhabdo risk
- Cholestyramine
 - CNI interactions
- Fish Oil
 - No data

DM

- 25% of pts have DM at time of txplt
- 25% of txplt pts develop NODAT within 3 years
- Culprit: tacrolimus (esp. if also on prednisone)





- Worse allograft and patient survival:
- NODAT conferred RR 3.8 for allograft failure (48% vs 70% after 12y)
- □ RR 1.5-3 for CV mortality



Tacrolimus

Decreased insulin secretionInsulin resistance


Treatment

- Lifestyle modifications
- Insulin usually needed
- *Metformin should be okay

CVD after transplant

pop.

Txp lowers CV mortality (4x) vs HD but not general



Lancet

CVD different in transplant patients?

- Different RFs?
 - HPT, phos, time on HD, LVH, wide PP?
 - Medial vessel wall concentric calcification
 - Vs traditional atherosclerosis/plaque
 - More pulm HTN, LVH, dCHF, wide PP
 - Increased arterial stiffness



Cancer (USRDS)

- RR >90
 - Non-melanoma skin
- RR 20-90
 - Kaposi's Sarcoma
 - Lymphoma
 - Uterine, Cervical, Vulvovaginal
- RR 5-20
 - Kidney
 - CNS
 - Melanoma
 - Leukemia
 - Larynx/Mouth
 - Endocrine
 - Hepatobiliary

- RR 2-5
 - Breast
 - Prostate
 - Lung
 - Colon
 - Esophagus
 - Pancreas
 - Ovary
 - Testis

3 years post transplant:7.5% get skin cancer7.5% get other cancers

Cancer screening recs

- Age appropriate cancer screening
 - Scope, PAP, testicular self exam, prostate/PSA, mammogram
- Renal US (native kidneys) annually
- Annual derm visits



- Avoid LIVE ATTENUATED vaccines after transplant:
 - Zoster, MMR, HPV, Yellow Fever
- Post Transplant
 - Flu every year
 - PNA every 5 years
 - TDAP every 10 years
 - HAV/HBV if not done already on HD

Posttransplant Infections

Rate of infection actually REDUCED 4x with a transplant compared to HD

Highest risk early on post transplant with higher doses of immune suppression

Post transplant prophylaxis


Common things are common!
 PNA/URI/UTI

Viral Infections

- Know "CMV status"
 - Did donor have CMV? Did recipient have CMV prior to tx?
 - Risk determines course of valcyte ppx post-op

D BK

- Increased immunosuppression
- +SV40 stain on Bx



Infection associated malignancy

- $\square EBV \rightarrow PTLD$
- □ HHV8 \rightarrow lymphoma & KS
- \square HPV \rightarrow SCC oropharynx, gyn
- $\Box HBV/HCV \rightarrow HCC$

Summary

- With better allograft survival rates there are more patients in the community with kidney transplants than ever before
- Always be aware of your patients' immune suppression and understand side effects and potential drug interactions
- Transplant nephrologists and community physicians will need to work together to manage the multitude of issues that can arise in transplant patients

Thank you!

- MSD Shadowing Program
 Interested? Contact me!
 marc.richards@gmail.com
- □ 561-325-1376



